https://m2.mtmt.hu/ hun 2026-09-23 10:35 JournalArticle 36433745 VALIDATED true 0 false 2026-08-12T13:21:13.364+0000 2026-04-13T10:03:59.502+0000 2025-11-13T10:01:33.224+0000 true 10090595 Maácz Fruzsina /api/author/10090595 Author Maácz Fruzsina (Neurofarmakológia) true 2026-08-04T09:07:32.603+0000 2025-12-18T15:21:19.608+0000 true 521 Szuper Admin /api/admin/521 Admin Szuper Admin (admin) true Admin 10025544 /api/admin/10025544 Lévayné Deseő Katalin (MTMT Központi admin) Lévayné Deseő Katalin true 10025544 true 2026-05-20T07:50:32.431+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Maácz, Fruzsina true true /api/journal/10015931 REVIEWED FRONTIERS IN CELLULAR NEUROSCIENCE 1662-5102 true false 10015931 false 10015931 true 1662-5102 Journal FOREIGN 19 1648613 1648613 13 2025 Funding 2059667 /api/funding/2059667 National Laboratory of Translational Neuroscience (TINL)(RRF-2.3.1-21-2022-00011) false true Funding 2059668 /api/funding/2059668 (Excellence PhD Scholarship of Gedeon Richter) false true true 2025 true true true false true false GOLD 2026-08-12 true https://real.mtak.hu/243214 1 0 1 1 0 1 1 0 1 1 1 1 1 1 0 0 1 1 1 1 0 14 14 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 1 1 1 1 Q2 false false false false 2025-11-16T08:47:37.652+0000 Doktori Iskola (SE); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Molekuláris Farmakológia Kutatócsoport (HRN KOKI) 3 13 3 5 0 true 10025544 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 128498620 /api/authorship/128498620 Maácz, Fruzsina [Maácz, Fruzsina (Neurofarmakológia), szerző] Molekuláris Farmakológia Kutatócsoport (HRN KOKI); Doktori Iskola (SE) 1 0.2 true false false Author 10090595 /api/author/10090595 Maácz Fruzsina (Neurofarmakológia) Maácz Fruzsina true true Maácz Fruzsina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128498621 /api/authorship/128498621 Bán, Erika Gyöngyi 2 0.2 false false false Bán Erika Gyöngyi true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128498622 /api/authorship/128498622 Brassai, Attila 3 0.2 false false false Brassai Attila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128498623 /api/authorship/128498623 Sperlágh, Beáta [Sperlágh, Beáta (Neurofarmakológia), szerző] Molekuláris Farmakológia Kutatócsoport (HRN KOKI) 4 0.2 false false false Author 10008942 /api/author/10008942 Sperlágh Beáta (Neurofarmakológia) Sperlágh Beáta true 10008942 true Sperlágh Beáta true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128498624 /api/authorship/128498624 Vizi, E. Sylvester ✉ [Vizi, E. Szilveszter (Neurofarmakológia...), szerző] Molekuláris Farmakológia Kutatócsoport (HRN KOKI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 5 0.2 false true true Author 10000023 /api/author/10000023 Vizi E. Szilveszter (Neurofarmakológia, neurokémia) Vizi E. Szilveszter true 10000023 true Vizi E. Sylvester true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 30156970 /api/publicationidentifier/30156970 DOI: 10.3389/fncel.2025.1648613 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3389/fncel.2025.1648613 https://doi.org/10.3389/fncel.2025.1648613 false true PublicationIdentifier 30260556 /api/publicationidentifier/30260556 WoS: 001619424600001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001619424600001 https://www.webofscience.com/wos/woscc/full-record/001619424600001 true true PublicationIdentifier 32686236 /api/publicationidentifier/32686236 REAL: 243214 SwordSource 36 /api/publicationsource/36 REAL PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true REAL REAL https://real.mtak.hu/@@@ true true 36 true GOLD true 243214 https://real.mtak.hu/243214 false true PublicationIdentifier 30260561 /api/publicationidentifier/30260561 Scopus: 105022610910 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105022610910 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105022610910 true true PublicationIdentifier 30260565 /api/publicationidentifier/30260565 PubMed: 41280334 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 41280334 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41280334&dopt=Abstract true true PublicationIdentifier 31158999 /api/publicationidentifier/31158999 Egyéb URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022610910&doi=10.3389%2Ffncel.2025.1648613&partnerID=40&md5=1736bc5ada1fb2b9561687b75555a7aa PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022610910&doi=10.3389%2Ffncel.2025.1648613&partnerID=40&md5=1736bc5ada1fb2b9561687b75555a7aa https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022610910&doi=10.3389%2Ffncel.2025.1648613&partnerID=40&md5=1736bc5ada1fb2b9561687b75555a7aa false true PublicationIdentifier 32260016 /api/publicationidentifier/32260016 Egyéb URL: https://www.scopus.com/pages/publications/105022610910?origin=resultslist PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/pages/publications/105022610910?origin=resultslist https://www.scopus.com/pages/publications/105022610910?origin=resultslist false true SjrRating 11564083 /api/sjrrating/11564083 sjr:Q2 (2025) Scopus - Cellular and Molecular Neuroscience FRONTIERS IN CELLULAR NEUROSCIENCE 1662-5102 29 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2804 /api/classificationexternal/2804 Scopus - Cellular and Molecular Neuroscience true 2804 true Q2 DIRECT true true Reference 69865096 /api/reference/69865096 1. Arvidsson 1997: Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems., J. Comp. Neurol., 378, p. 454, DOI: 10.1002/(SICI)1096-9861(19970224)378:4&lt;&gt;3.0.CO;2-1 1 10.1002/(SICI)1096-9861(19970224)378:4&lt;&gt;3.0.CO;2-1 false true Reference 69865097 /api/reference/69865097 2. Bowyer 1984: Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes., J. Pharmacol. Exp. Ther., 229, p. 671, DOI: 10.1016/S0022-3565(25)21871-7 2 10.1016/S0022-3565(25)21871-7 false true Reference 69865098 /api/reference/69865098 3. Brachtendorf 2015: A use-dependent increase in release sites drives facilitation at calretinin-deficient cerebellar parallel-fiber synapses., Front. Cell. Neurosci., 9, p. 27, DOI: 10.3389/fncel.2015.00027 3 10.3389/fncel.2015.00027 false true Reference 69865099 /api/reference/69865099 4. Bravo 2005: New transport assay demonstrates vesicular acetylcholine transporter has many alternative substrates., Neurochem. Int., 47, p. 243, DOI: 10.1016/j.neuint.2005.05.002 4 10.1016/j.neuint.2005.05.002 false true Reference 69865100 /api/reference/69865100 5. Brodie 1956: Serotonin-releasing activity limited to rauwolfia alkaloids with tranquilizing action., Science, 123, p. 992, DOI: 10.1126/science.123.3205.992-a 5 10.1126/science.123.3205.992-a false true Reference 69865101 /api/reference/69865101 6. Carbon 2017: Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis., J. Clin. Psychiatry, 78, p. e264, DOI: 10.4088/JCP.16r10832 6 10.4088/JCP.16r10832 false true Reference 69865102 /api/reference/69865102 7. Carlsson 1965: The mechanism of action of neuroleptics and antidepressive drugs., Lakartidningen, 62, p. 1978 7 false true Reference 69865103 /api/reference/69865103 8. Carlsson 1978: Antipsychotic drugs, neurotransmitters, and schizophrenia., Am. J. Psychiatry, 135, p. 165, DOI: 10.1176/ajp.135.2.165 8 10.1176/ajp.135.2.165 false true Reference 69865104 /api/reference/69865104 9. Caroff 2018: Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review., J. Comp. Eff. Res., 7, p. 135, DOI: 10.2217/cer-2017-0065 9 10.2217/cer-2017-0065 false true Reference 69865105 /api/reference/69865105 10. Chaudhry 2008: Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances., Annu. Rev. Pharmacol. Toxicol., 48, p. 277, DOI: 10.1146/annurev.pharmtox.46.120604.141146 10 10.1146/annurev.pharmtox.46.120604.141146 false true Reference 69865106 /api/reference/69865106 11. Chen 1992: An in vivo 19F NMR study of isoflurane elimination as a function of age in rat brain., NMR Biomed., 5, p. 121, DOI: 10.1002/nbm.1940050304 11 10.1002/nbm.1940050304 false true Reference 69865107 /api/reference/69865107 12. Csölle 2013: Neurochemical changes in the mouse Hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors., PLoS One, 8, p. e66547, DOI: 10.1371/journal.pone.0066547 12 10.1371/journal.pone.0066547 false true Reference 69865108 /api/reference/69865108 13. Dluzen 2008: Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function., Neuroscience, 154, p. 1488, DOI: 10.1016/j.neuroscience.2008.04.051 13 10.1016/j.neuroscience.2008.04.051 false true Reference 69865109 /api/reference/69865109 14. Dorsey 2013: Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study., J. Huntingtons Dis., 2, p. 509, DOI: 10.3233/JHD-130071 14 10.3233/JHD-130071 false true Reference 69865110 /api/reference/69865110 15. Eiden 2004: The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine., Pflugers Arch., 447, p. 636, DOI: 10.1007/s00424-003-1100-5 15 10.1007/s00424-003-1100-5 false true Reference 69865111 /api/reference/69865111 16. Esper 2015: Blood/gas partition coefficients for isoflurane, sevoflurane, and desflurane in a clinically relevant patient population., Anesth. Analg., 120, p. 45, DOI: 10.1213/ANE.0000000000000516 16 10.1213/ANE.0000000000000516 false true Reference 69865112 /api/reference/69865112 17. Gölöncsér 2024: P2X7 receptor inhibition alleviates mania-like behavior independently of interleukin-1β., iScience, 27, p. 109284, DOI: 10.1016/j.isci.2024.109284 17 10.1016/j.isci.2024.109284 false true Reference 69865113 /api/reference/69865113 18. Grigoriadis 2017: Pharmacologic characterization of Valbenazine (NBI-98854) and its metabolites., J. Pharmacol. Exp. Ther., 361, p. 454, DOI: 10.1124/jpet.116.239160 18 10.1124/jpet.116.239160 false true Reference 69865114 /api/reference/69865114 19. Hennings 1999: Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices., J. Neurochem., 73, p. 1043, DOI: 10.1046/j.1471-4159.1999.0731043.x 19 10.1046/j.1471-4159.1999.0731043.x false true Reference 69865115 /api/reference/69865115 20. Henry 1989: Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles., Biochem. Pharmacol., 38, p. 2395, DOI: 10.1016/0006-2952(89)90082-8 20 10.1016/0006-2952(89)90082-8 false true Reference 69865116 /api/reference/69865116 21. Iv 2024: Role of vesicular monoamine transporter-2 for treating attention deficit hyperactivity disorder: a review., Psychopharmacology, 241, p. 2191, DOI: 10.1007/s00213-024-06686-7 21 10.1007/s00213-024-06686-7 false true Reference 69865117 /api/reference/69865117 22. Johnson 1981: Proton: substrate stoichiometries during active transport of biogenic amines in chromaffin ghosts., J. Biol. Chem., 256, p. 5773, DOI: 10.1016/S0021-9258(19)69274-4 22 10.1016/S0021-9258(19)69274-4 false true Reference 69865118 /api/reference/69865118 23. Lakatos 2020: Roles played by the Na(+)/ca(2+) exchanger and hypothermia in the prevention of ischemia-induced carrier-mediated efflux of catecholamines into the extracellular space: implications for stroke therapy., Neurochem. Res., 45, p. 16, DOI: 10.1007/s11064-019-02842-0 23 10.1007/s11064-019-02842-0 false true Reference 69865119 /api/reference/69865119 24. Levi 1974: Exchange of neurotransmitter amino acid at nerve endings can simulate high affinity uptake., Nature, 250, p. 735, DOI: 10.1038/250735a0 24 10.1038/250735a0 false true Reference 69865120 /api/reference/69865120 25. Metzger 2002: Inhibitory effect of reserpine on dopamine transporter function., Eur. J. Pharmacol., 456, p. 39, DOI: 10.1016/s0014-2999(02)02647-x 25 10.1016/s0014-2999(02)02647-x false true Reference 69865121 /api/reference/69865121 26. Miguel Telega 2024: Reserpine-induced rat model for depression: Behavioral, physiological and PET-based dopamine receptor availability validation., Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 133, p. 111013, DOI: 10.1016/j.pnpbp.2024.111013 26 10.1016/j.pnpbp.2024.111013 false true Reference 69865122 /api/reference/69865122 27. Milusheva 2008: Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment., J. Neurochem., 105, p. 360, DOI: 10.1111/j.1471-4159.2007.05141.x 27 10.1111/j.1471-4159.2007.05141.x false true Reference 69865123 /api/reference/69865123 28. Milusheva 1994: Release of acetylcholine and noradrenaline from the cholinergic and adrenergic afferents in rat hippocampal CA1, CA3 and dentate gyrus regions., Eur. J. Neurosci., 6, p. 187, DOI: 10.1111/j.1460-9568.1994.tb00260.x 28 10.1111/j.1460-9568.1994.tb00260.x false true Reference 69865124 /api/reference/69865124 29. Milusheva 1996: Effect of hypoxia and glucose deprivation on ATP level, adenylate energy charge and [Ca2+]o-dependent and independent release of [3H]dopamine in rat striatal slices., Neurochem. Int., 28, p. 501, DOI: 10.1016/0197-0186(95)00129-8 29 10.1016/0197-0186(95)00129-8 false true Reference 69865125 /api/reference/69865125 30. Pahlavani 2024: Possible role of exercise therapy on depression: effector neurotransmitters as key players., Behav. Brain Res., 459, p. 114791, DOI: 10.1016/j.bbr.2023.114791 30 10.1016/j.bbr.2023.114791 false true Reference 69865126 /api/reference/69865126 31. Porta 2008: Tourette's syndrome and role of tetrabenazine: review and personal experience., Clin. Drug Investig., 28, p. 443, DOI: 10.2165/00044011-200828070-00006 31 10.2165/00044011-200828070-00006 false true Reference 69865127 /api/reference/69865127 32. Qian 2023: Repeated reserpine treatment induces depressive-like behaviors accompanied with hippocampal impairment and synapse deficit in mice., Brain Res., 1819, p. 148541, DOI: 10.1016/j.brainres.2023.148541 32 10.1016/j.brainres.2023.148541 false true Reference 69865128 /api/reference/69865128 33. Raiteri 1974: A simple apparatus for studying the release of neurotransmitters from synaptosomes., Eur. J. Pharmacol., 25, p. 411, DOI: 10.1016/0014-2999(74)90272-6 33 10.1016/0014-2999(74)90272-6 false true Reference 69865129 /api/reference/69865129 34. Raiteri 1979: Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine., J. Pharmacol. Exp. Ther., 208, p. 195, DOI: 10.1016/S0022-3565(25)31548-X 34 10.1016/S0022-3565(25)31548-X false true Reference 69865130 /api/reference/69865130 35. Raiteri 1990: Glycine stimulates [3H]noradrenaline release by activating a strychnine-sensitive receptor present in rat hippocampus., Eur. J. Pharmacol., 184, p. 239, DOI: 10.1016/0014-2999(90)90615-d 35 10.1016/0014-2999(90)90615-d false true Reference 69865131 /api/reference/69865131 36. Raiteri 2015: Multiple functions of neuronal plasma membrane neurotransmitter transporters., Prog. Neurobiol., 134, p. 1, DOI: 10.1016/j.pneurobio.2015.08.002 36 10.1016/j.pneurobio.2015.08.002 false true Reference 69865132 /api/reference/69865132 37. Raiteri 2002: Coexistence and function of different neurotransmitter transporters in the plasma membrane of CNS neurons., Prog. Neurobiol., 68, p. 287, DOI: 10.1016/s0301-0082(02)00059-x 37 10.1016/s0301-0082(02)00059-x false true Reference 69865133 /api/reference/69865133 38. Roman 2021: Contribution of analog signaling to neurotransmitter interactions and behavior: role of transporter-mediated nonquantal dopamine release., Physiol. Rep., 9, p. e15088, DOI: 10.14814/phy2.15088 38 10.14814/phy2.15088 false true Reference 69865134 /api/reference/69865134 39. Ross 1979: Release of 3H-noradrenaline from the rat vas deferens under various in vitro conditions., Acta Physiol. Scand., 105, p. 338, DOI: 10.1111/j.1748-1716.1979.tb06349.x 39 10.1111/j.1748-1716.1979.tb06349.x false true Reference 69865135 /api/reference/69865135 40. Scherman 1984: Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding., Mol. Pharmacol., 25, p. 113, DOI: 10.1016/S0026-895X(25)15021-9 40 10.1016/S0026-895X(25)15021-9 false true Reference 69865136 /api/reference/69865136 41. Schneider 2021: Pharmacokinetics of Deutetrabenazine and tetrabenazine: dose proportionality and food effect., Clin. Pharmacol. Drug Dev., 10, p. 647, DOI: 10.1002/cpdd.882 41 10.1002/cpdd.882 false true Reference 69865137 /api/reference/69865137 42. Sershen 1997: Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus., Neuroscience, 77, p. 121, DOI: 10.1016/s0306-4522(96)00425-3 42 10.1016/s0306-4522(96)00425-3 false true Reference 69865138 /api/reference/69865138 43. Skor 2017: Differences in Dihydrotetrabenazine isomer concentrations following Administration of Tetrabenazine and Valbenazine., Drugs R&D, 17, p. 449, DOI: 10.1007/s40268-017-0202-z 43 10.1007/s40268-017-0202-z false true Reference 69865139 /api/reference/69865139 44. Sreemantula 2004: Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats., BMC Pharmacol., 4, p. 30, DOI: 10.1186/1471-2210-4-30 44 10.1186/1471-2210-4-30 false true Reference 69865140 /api/reference/69865140 45. Strawbridge 2023: The effects of reserpine on depression: a systematic review., J. Psychopharmacol., 37, p. 248, DOI: 10.1177/02698811221115762 45 10.1177/02698811221115762 false true Reference 69865141 /api/reference/69865141 46. Tod 2024: Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue., Br. J. Pharmacol., 181, p. 5094, DOI: 10.1111/bph.17348 46 10.1111/bph.17348 false true Reference 69865142 /api/reference/69865142 47. Török 2004: Presynaptic alpha2-receptors regulate reverse Na+/Ca2+−exchange and transmitter release in Na+−loaded peripheral sympathetic nerves., Neurochem. Int., 45, p. 699, DOI: 10.1016/j.neuint.2004.03.002 47 10.1016/j.neuint.2004.03.002 false true Reference 69865143 /api/reference/69865143 48. Vizi 1988: Origin of ATP release in the rat vas deferens: concomitant measurement of [3H]noradrenaline and [14C]ATP., Eur. J. Pharmacol., 158, p. 69, DOI: 10.1016/0014-2999(88)90254-3 48 10.1016/0014-2999(88)90254-3 false true Reference 69865144 /api/reference/69865144 49. Vizi 1998: Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions., Hippocampus, 8, p. 566, DOI: 10.1002/(SICI)1098-1063(1998)8:6&lt;566::AID-HIPO2&gt;3.0.CO;2-W 49 10.1002/(SICI)1098-1063(1998)8:6&lt;566::AID-HIPO2&gt;3.0.CO;2-W false true Reference 69865145 /api/reference/69865145 50. Westphalen 2009: Nicotinic receptor-evoked hippocampal norepinephrine release is highly sensitive to inhibition by isoflurane., Br. J. Anaesth., 102, p. 355, DOI: 10.1093/bja/aen387 50 10.1093/bja/aen387 false true Reference 69865146 /api/reference/69865146 51. Wu 2024: Transport and inhibition mechanisms of human VMAT2., Nature, 626, p. 427, DOI: 10.1038/s41586-023-06926-4 51 10.1038/s41586-023-06926-4 false true Reference 69865147 /api/reference/69865147 52. Yang 2020: The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures., Psychopharmacology, 237, p. 2845, DOI: 10.1007/s00213-020-05578-w 52 10.1007/s00213-020-05578-w false true Reference 69865148 /api/reference/69865148 53. Zhang 2024: Mining of neurological adverse events associated with valbenazine: a post-marketing analysis based on FDA adverse event reporting system., Gen. Hosp. Psychiatry, 90, p. 22, DOI: 10.1016/j.genhosppsych.2024.06.005 53 10.1016/j.genhosppsych.2024.06.005 false true Reference 69865149 /api/reference/69865149 54. Zsilla 2018: 3,4-methylenedioxymethamphetamine, mephedrone, and beta-phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake., Eur. J. Pharmacol., 837, p. 72, DOI: 10.1016/j.ejphar.2018.08.037 54 10.1016/j.ejphar.2018.08.037 false true /api/publication/36433745 Maácz Fruzsina et al. The role of the vesicular monoamine transporter 2 in the inhibitory effect of tetrabenazine and valbenazine compared to reserpine on the vesicular release of monoamine transmitters. (2025) FRONTIERS IN CELLULAR NEUROSCIENCE 1662-5102 19<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10090595"><a href="/gui2/?type=authors&mode=browse&sel=10090595" target="_blank">Maácz Fruzsina (<span class="authorship-author-name">Maácz Fruzsina</span> <span class="authorAux-mtmt"> Neurofarmakológia</span>) </a> </span> <span class="author-affil"><span title="HUN-REN Kísérleti Orvostudományi Kutatóintézet">HRN KOKI</span>/Molekuláris Farmakológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/Doktori Iskola</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Bán Erika Gyöngyi </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Brassai Attila </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10008942"><a href="/gui2/?type=authors&mode=browse&sel=10008942" target="_blank">Sperlágh Beáta (<span class="authorship-author-name">Sperlágh Beáta</span> <span class="authorAux-mtmt"> Neurofarmakológia</span>) </a> </span> <span class="author-affil"><span title="HUN-REN Kísérleti Orvostudományi Kutatóintézet">HRN KOKI</span>/Molekuláris Farmakológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000023"><a href="/gui2/?type=authors&mode=browse&sel=10000023" target="_blank">Vizi E. Sylvester ✉ (<span class="authorship-author-name">Vizi E. Szilveszter</span> <span class="authorAux-mtmt"> Neurofarmakológia, neurokémia</span>) </a> </span> <span class="author-affil"><span title="HUN-REN Kísérleti Orvostudományi Kutatóintézet">HRN KOKI</span>/Molekuláris Farmakológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36433745" target="_blank">The role of the vesicular monoamine transporter 2 in the inhibitory effect of tetrabenazine and valbenazine compared to reserpine on the vesicular release of monoamine transmitters</a></div> <div> <span class="journal-title">FRONTIERS IN CELLULAR NEUROSCIENCE</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/1662-5102">1662-5102</a>)</span>: <span class="journal-volume">19</span> <span class="page"> Paper 1648613. 13 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3389/fncel.2025.1648613" target="_blank" href="https://doi.org/10.3389/fncel.2025.1648613"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001619424600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001619424600001"> WoS </a> </span> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:black" title="243214" target="_blank" href="https://real.mtak.hu/243214"> REAL </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105022610910" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105022610910"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="41280334" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41280334&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022610910&doi=10.3389%2Ffncel.2025.1648613&partnerID=40&md5=1736bc5ada1fb2b9561687b75555a7aa" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-105022610910&doi=10.3389%2Ffncel.2025.1648613&partnerID=40&md5=1736bc5ada1fb2b9561687b75555a7aa"> Egyéb URL </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/pages/publications/105022610910?origin=resultslist" target="_blank" href="https://www.scopus.com/pages/publications/105022610910?origin=resultslist"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cellular and Molecular Neuroscience&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 1</span> | Független: 1 | Függő: 0 | Nem jelölt: 0 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36433745&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 14 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36433745</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">DOI XML</span> </div> <div class="funder"> National Laboratory of Translational Neuroscience (TINL)(RRF-2.3.1-21-2022-00011), (Excellence PhD Scholarship of Gedeon Richter) </div> <div class="lastModified">Utolsó módosítás: 2026.04.13. 12:03 Turek Márta (KOKI admin 4) </div> <div class="lockedBy">Központi kezelésű 2026.05.20. 09:50 Lévayné Deseő Katalin (MTMT Központi admin) </div> </div></div>